1. Home
  2. AADI vs SCNX Comparison

AADI vs SCNX Comparison

Compare AADI & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AADI
  • SCNX
  • Stock Information
  • Founded
  • AADI 2011
  • SCNX 2010
  • Country
  • AADI United States
  • SCNX United States
  • Employees
  • AADI N/A
  • SCNX N/A
  • Industry
  • AADI Biotechnology: Pharmaceutical Preparations
  • SCNX Other Pharmaceuticals
  • Sector
  • AADI Health Care
  • SCNX Health Care
  • Exchange
  • AADI Nasdaq
  • SCNX Nasdaq
  • Market Cap
  • AADI 59.4M
  • SCNX 65.4M
  • IPO Year
  • AADI N/A
  • SCNX 2020
  • Fundamental
  • Price
  • AADI $2.98
  • SCNX $4.63
  • Analyst Decision
  • AADI Hold
  • SCNX
  • Analyst Count
  • AADI 3
  • SCNX 0
  • Target Price
  • AADI $1.75
  • SCNX N/A
  • AVG Volume (30 Days)
  • AADI 863.3K
  • SCNX 10.5K
  • Earning Date
  • AADI 03-12-2025
  • SCNX 02-10-2025
  • Dividend Yield
  • AADI N/A
  • SCNX N/A
  • EPS Growth
  • AADI N/A
  • SCNX N/A
  • EPS
  • AADI N/A
  • SCNX 3.55
  • Revenue
  • AADI $25,070,000.00
  • SCNX N/A
  • Revenue This Year
  • AADI $8.43
  • SCNX $1,085.75
  • Revenue Next Year
  • AADI $5.41
  • SCNX N/A
  • P/E Ratio
  • AADI N/A
  • SCNX $2.01
  • Revenue Growth
  • AADI 7.80
  • SCNX 166.67
  • 52 Week Low
  • AADI $1.21
  • SCNX $3.69
  • 52 Week High
  • AADI $3.81
  • SCNX $44.56
  • Technical
  • Relative Strength Index (RSI)
  • AADI 50.12
  • SCNX N/A
  • Support Level
  • AADI $2.91
  • SCNX N/A
  • Resistance Level
  • AADI $3.27
  • SCNX N/A
  • Average True Range (ATR)
  • AADI 0.27
  • SCNX 0.00
  • MACD
  • AADI -0.06
  • SCNX 0.00
  • Stochastic Oscillator
  • AADI 11.68
  • SCNX 0.00

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

About SCNX Scienture Holdings Inc. Common Stock

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

Share on Social Networks: